Our Focus

severe diseases

Each person inherits features in the form of genes, which are made up of a molecule called DNA. Genetic diseases involve problems with the functioning genes. Our gene therapy technology intends to make up for genetic defects by creating a functioning copy of the genes that express functional proteins and correct or address the underlying cause of the disease. We believe gene therapy has the potential to provide transformative, disease-modifying effects – potentially with life-long clinical benefits, based on a single administration.

leading the revolution –

how our gene therapy works

Our gene therapy process works by genetically modifying a patient’s own cells by adding a functional copy of the gene of interest. We have extensive expertise in viral vector design and manufacturing and transduction, which we have developed into a potent gene therapy platform with potentially broad applications in a wide variety of indications with significant medical needs.


Our Lenti-DTM product candidate has the potential to stabilize or prevent progression of cerebral adrenoleukodystrophy (CALD), a fatal and rare genetic disorder that affects the nervous system of boys and men with one treatment. Our approach involves inserting a functional copy of the ABCD1 gene in the patient’s hematopoietic stem cells outside the body, then re-introducing the genetically modified cells into the patient.

Lenti-D is currently being evaluated in the Starbeam Study, a Phase 2/3 clinical study, for its effectiveness in treating CALD. Promising, but early clinical proof-of-concept results for two patients in a French study sponsored by INSERM and licensed by bluebird bio were reported in the November 2009 issue of Science.

The primary efficacy endpoint for the Starbeam Study is the proportion of patients with no major functional disabilities (MFDs) at 24 months post treatment. MFDs are six components of the neurological function score (NFS) that, if present, would have a profound negative impact on patients’ lives: loss of communication, cortical blindness, tube feeding, total incontinence, wheelchair dependence and complete loss of voluntary movement. Secondary endpoints include Loes score (a method for quantifying demyelination and atrophy on brain MRI in patients with ALD), NFS (a scoring system assessing clinical deficits of CALD across 15 functional domains), gadolinium enhancement on MRI (an indicator of active neuroinflammation) and safety.

We presented the first, interim data from 17 treated patients in the Starbeam Study at the American Academy of Neurology (AAN) Annual Meeting 2016. Highlights of those findings include:

  • All patients remain free of MFDs, and 16 of 17 patients had NFS stabilization (change of
  • Fourteen of 17 patients had a stable Loes score (change of ≤ 5 points or an absolute Loes score ≤ 9).
  • Sixteen of 17 had resolution of gadolinium enhancement by month six. Re-emergence of diffuse contrast enhancement was seen in five patients at month 12. Of those five patients, the two with at least 18 months of follow up showed resolution of gadolinium enhancement at month 18.
  • The safety profile of Lenti-D treatment appears consistent with myeloablative conditioning with one possibly drug-related serious adverse event (Grade 3 BK-mediated viral cystitis) and one possibly drug-related adverse event (Grade 1 tachycardia). Both were resolved with standard measures.
  • Integration site analyses have demonstrated polyclonal reconstitution in all subjects without evidence of clonal dominance to date.

learn how gene therapy works to potentially treat CALD

learn more about adrenoleukodystrophy

our ongoing clinical trial in CALD

The Starbeam Study is a Phase 2/3 clinical trial that is evaluating our Lenti-D product candidate for the treatment of CALD.
learn more about our Starbeam Study


encouraging clinical data support our gene therapy’s potential
Our LentiGlobin® BB305 product candidate aims to treat transfusion-dependent β-thalassemia (also known as β-thalassemia major) and severe sickle cell disease (SCD). LentiGlobin works by inserting a functional human beta-globin gene into a patient’s own hematopoietic stem cells outside the body (ex vivo) and then transplanting those modified cells into the patient’s blood stream through infusion, also known as autologous stem cell transplantation.

A unique amino acid substitution in the beta-globin gene in LentiGlobin confers important anti-sickling properties to help potentially address the most severe forms of sickle cell disease. Promising results from a preclinical proof-of-concept study using gene therapy to treat sickle cell disease were published in Science.

We currently have three ongoing studies evaluating our LentiGlobin therapy for the treatment of transfusion-dependent β-thalassemia and severe SCD – the Northstar Study in transfusion-dependent β-thalassemia, the HGB-205 study in transfusion-dependent β-thalassemia or severe SCD and the HGB-206 study in severe SCD. As we continue to gather a growing body of data for LentiGlobin, we are learning and better understanding the potential clinical benefit our therapy can have on patients suffering from these diseases.

transfusion-dependent β-thalassemia (β-thalassemia major)
At the 57th American Society of Hematology (ASH) 2015 Annual Meeting, we presented data on 17 patients with transfusion-dependent β-thalassemia from the Northstar and HGB-205 studies. Findings include:

    • All patients with non-β00 genotypes followed for at least six months are transfusion independent, with the longest transfusion independence for 23.4 months.
    • In the NorthStar Study, median HbAT87Q production, or therapeutic globin, at six months follow up in the nine patients with non-β00 genotypes was 9 g/dL, with total hemoglobin ranging from 9.1 to 12.2 g/dL. The four patients with the β00 genotype were producing a median of 5.0 g/dL HbAT87Q
    • In the HGB-205 study, Subject 1201 was producing total hemoglobin of 10.8 g/dL, of which 7.9 g/dL was HbAT87Q, and Subject 1202 was producing total hemoglobin of 13.1 g/dL, of which 10.3 g/dL was HbAT87Q.
    • Patients with the β00 genotype are experiencing transfusion reductions between 33 and 100 percent, indicating a potential benefit, as these patients may no longer require chronic transfusions. By reducing the number of transfusions required, we reduce the risks associated with transfusions, like iron overload.

The data presented at the 2015 ASH Annual Meeting build on the data previously presented at the 20th Annual Congress of the European Hematology Association (EHA) and the 2014 American Society of Hematology Annual Meeting.

severe sickle cell disease
Also at the 2015 ASH Annual Meeting, we presented updated data on the first ever patient with severe SCD treated with gene therapy from our HGB-205 study and the first data on patients with severe SCD from our HGB-206 study.

      • At the 12-month post-drug infusion follow up for Subject 1204 in the HGB-205 study, the proportion of anti-sickling hemoglobin (HbAT87Q + HbF) accounted for 49 percent of all hemoglobin production (47 percent HbAT87Q + 2 percent HbF), remaining well above the minimum 30 percent threshold believed to have a therapeutic effect.
      • Prior to infusion, Subject 1204 required chronic blood transfusions; he was successfully weaned off of transfusions and remains free of transfusions and complications from SCD for nine months.
      • In the HGB-206 study, we have manufactured LentiGlobin for four patients, and three patients have been infused. Subjects 1301 and 1303 have three and six months of follow up post-infusion, respectively.
        • At the six-month post-infusion follow up for Subject 1303, the proportion of anti-sickling hemoglobin accounted for 16 percent of all hemoglobin production (12 percent HbAT87Q + 4 percent HbF).
        • At the three-month post-infusion follow up for Subject 1301, the proportion of anti-sickling hemoglobin accounted for 17 percent of all hemoglobin production (4 percent HbAT87Q + 13 percent HbF).
      • Longer follow up data and additional subjects are required to determine the extent of HbAT87Q production and clinical impact of LentiGlobin BB303 in severe SCD.

The safety profile in the infused patients is consistent with autologous transplantation and no drug product-related grade >3 adverse events have been reported.

learn how gene therapy works to potentially treat β-thalassemia

learn more about β-thalassemia learn more about Sickle cell disease

our ongoing clinical trials in β-thalassemia and sickle cell disease

Our LentiGlobin product candidate is being studied in three ongoing clinical trials in patients with transfusion-dependent β-thalassemia and severe sickle cell disease.
learn more about our ongoing clinical trials